Evaxion welcomes per norlÉn as new ceo.

Copenhagen, denmark, oct. 05, 2022 (globe newswire) -- evaxion biotech a/s (nasdaq: evax) (“evaxion” or the “company”), a clinical-stage biotechnology company specializing in the development of ai-driven immunotherapies, announces that its new chief executive officer (ceo) per norlÉn has joined the company on october 3rd.
EVAX Ratings Summary
EVAX Quant Ranking